London
· Delayed Price · Currency is GBP · Price in GBXOndine Biomedical Statistics
Total Valuation
Ondine Biomedical has a market cap or net worth of GBP 21.49 million. The enterprise value is 20.99 million.
| Market Cap | 21.49M |
| Enterprise Value | 20.99M |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ondine Biomedical has 277.29 million shares outstanding. The number of shares has increased by 13.24% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 277.29M |
| Shares Change (YoY) | +13.24% |
| Shares Change (QoQ) | +21.20% |
| Owned by Insiders (%) | 41.09% |
| Owned by Institutions (%) | 31.95% |
| Float | 163.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.09 |
| PB Ratio | n/a |
| P/TBV Ratio | 1,956.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.54 |
| EV / Sales | 22.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.89 |
Financial Position
The company has a current ratio of 0.80, with a Debt / Equity ratio of 18.47.
| Current Ratio | 0.80 |
| Quick Ratio | 0.36 |
| Debt / Equity | 18.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -228.20 |
Financial Efficiency
Return on equity (ROE) is -685.59% and return on invested capital (ROIC) is -330.37%.
| Return on Equity (ROE) | -685.59% |
| Return on Assets (ROA) | -159.71% |
| Return on Capital (ROIC) | -330.37% |
| Revenue Per Employee | 52,482 |
| Profits Per Employee | -458,464 |
| Employee Count | 18 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 0.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -12.43% |
| 50-Day Moving Average | 7.55 |
| 200-Day Moving Average | 7.70 |
| Relative Strength Index (RSI) | 45.61 |
| Average Volume (20 Days) | 1,013,761 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ondine Biomedical had revenue of GBP 944,679 and -8.25 million in losses. Loss per share was -0.04.
| Revenue | 944,679 |
| Gross Profit | 567,154 |
| Operating Income | -8.44M |
| Pretax Income | -8.25M |
| Net Income | -8.25M |
| EBITDA | -8.33M |
| EBIT | -8.44M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 704,173 in cash and 202,927 in debt, giving a net cash position of 501,247 or 0.00 per share.
| Cash & Cash Equivalents | 704,173 |
| Total Debt | 202,927 |
| Net Cash | 501,247 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 10,985 |
| Book Value Per Share | 0.00 |
| Working Capital | -453,261 |
Cash Flow
In the last 12 months, operating cash flow was -7.26 million and capital expenditures -7,516, giving a free cash flow of -7.27 million.
| Operating Cash Flow | -7.26M |
| Capital Expenditures | -7,516 |
| Free Cash Flow | -7.27M |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | 60.04% |
| Operating Margin | -893.82% |
| Pretax Margin | -873.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -769.65% |
Dividends & Yields
Ondine Biomedical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.24% |
| Shareholder Yield | -13.24% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ondine Biomedical has an Altman Z-Score of -101.68. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -101.68 |
| Piotroski F-Score | n/a |